Genefitletics, a pioneering force in predictive human biology, has introduced VASCOMATH, a groundbreaking CVD prediction model. Leveraging insights from gut and oral microbiome gene expression, this cutting-edge model stands as India’s foremost microbiome-centric tool for anticipating cardiovascular diseases (CVD).

VASCOMATH represents a pivotal stride in understanding molecular mechanisms underlying CVD, offering personalized interventions utilizing nutrition as a therapeutic agent. The launch of VASCOMATH aligns with Genefitletics’ repertoire of predictive human biology models, including the recent addition of PREDIGLYM, aimed at type 2 diabetes prediction.

Founded in 2019, Genefitletics had previously developed PROTEBA, a revolutionary systems biology platform harnessing machine learning to delve into molecular-level chemistry. This platform pioneers disease-altering nutrition interventions, redefining approaches to human health rejuvenation.

Sushant Kumar, Founder & CEO of Genefitletics, emphasizes the global burden of cardiovascular diseases, citing them as a leading cause of preventable deaths worldwide. In India specifically, heart diseases account for 27 percent of mortality rates. Kumar stresses the need to understand the microbiome, an often-overlooked facet, in combatting chronic diseases. He criticizes the prevalent pharmaceutical-centric healthcare approach, highlighting its failure to address root causes.

Kumar underscores the microbiome's significance as one of the earliest inhabitants on Earth, particularly in the context of cardiovascular health. Scientific investigations focus on trillions of microbes within the human body and their impact on overall health. Chronic diseases, including cardiovascular ailments, stem from prolonged inflammation, leaving indiscernible molecular imprints that traditional clinical tests fail to detect.

Genefitletics’ flagship platform, PROTEBA, amalgamates system biology and machine learning to analyze vast molecular data from oral, vaginal, and gut microbiome gene expressions. Through this process, predictive models are constructed to identify pre-symptomatic molecular signatures associated with chronic diseases across 50+ biological pathways/biomarkers. Precision nutrition interventions are then tailored to eliminate proinflammatory molecules, thereby mitigating the risk of disease onset.

The introduction of VASCOMATH marks a significant leap in predictive healthcare, poised to revolutionize CVD risk assessment and prevention strategies. Genefitletics' innovative approach to leveraging microbiome insights could pave the way for a paradigm shift in disease prediction and targeted intervention, reshaping the landscape of preventive healthcare in India and beyond.